- Quest Diagnostics and a panel of
academic partners testified to the potential of the diagnostic
solutions developed by the Company based on the new paradigm
provided by the molecular combing
Regulatory News:
Genomic Vision (Paris:GV) (Euronext: FR0011799907 – GV),
a company specialized in the development of diagnostic tests for
the early detection of cancers and genetic diseases, today reports
of its first R&D Day who took place on May 10, to the Imagine
Institute (Necker Hospital) in Paris, in front of a panel of
individual and institutional investors, financial analysts and
journalists. This first event was aimed at presenting a global
overview of the IVD activities of the Company with its historical
industrial partner Quest Diagnostics and with several academic
teams.
During an inaugural speech, Stanislas Lyonnet, Ph.D., head of
Imagine Institute, directeur de l’Institut Imagine, called back the
commitment of the Institute in the research on genetic pediatric
diseases and the outlines of the partnership with Genomic Vision.
“Our Institute is a reference center for the molecular combing
technology use since almost two years. This technology can meet our
stringent requirements: establish a precise and early diagnosis of
the pathology, identify the genes and the mechanisms involved,
evaluate the different therapeutic options and transform the
patient’s healthcare.”
Subsequently, Jay Wohlgemuth, M.D., Senior VP, CMO of Quest
Diagnostics and Edward Ginns, M.D, Ph.D, Medical director -
Neurology of Quest Diagnostics, presented the move of Quest
strategy from a lab company to an added value diagnostic service
provider and reminded the importance for Quest of investing in new
products and technologies. He therefore insisted on the strong link
between both companies by using the molecular combing technology as
well as co-developing diagnostic tests.Jay Wohlgemuth declared: “We
at Quest Diagnostics have been collaborating with GV for over seven
years and we are highly committed to our collaboration through
providing samples and data to develop applications for the DNA
combing technology. Applications take the form of biomarkers for
pharmaceutical development and as a clinical diagnostics tool for
genetic diseases. Our first success is the development of the FSHD
combing testing as a standard in the U.S. I’m committed to continue
our collaboration with GV.”
About the development of the BRCA test in the breast and ovarian
cancer early detection, Jay Wohlgemuth specified: “The DNA combing
technology has been used to explore a BRCA test for hereditary
breast and ovarian cancer. We are currently performing a clinical
study with GV using Quest Diagnostic’s samples and that process is
ongoing. When data is available, it will be made public.”Aaron
Bensimon, CEO and co-founder of Genomic Vision, indicated:
« For the development of such a predisposition test, the
environment profoundly evolved during the last years. BRCA test was
initiated in 2012 and we had focused our analysis on the large
rearrangements of BRCA1 and BRCA2 genes. Today, we know that the
screening tests for breast hereditary cancer are evaluating a wider
panel of more than 30 genes. Our partner Quest Diagnostics and
Genomic Vision have to reposition the BRCA test on this basis and
this is on what we work at the moment.”
On the SMA diagnostic test, the representatives of Quest
Diagnosis explained: “SMA,
spinal muscular atrophy, is an hereditary complex
disease with a large portion of healthy carrier of the recessive
gene responsible for one of the most common muscular dystrophies in
the US and around the world. Through our collaboration with Genomic
Vision we believe that we will be able to uncover biomarkers
crucial to the detection of potential carriers of this disease. To
achieve Quest Diagnostics are collaborating through the provision
of samples to fully characterize the SMA genomic region. This work
is ongoing and we hope to have results over the coming year.”
Pr Nicolas Levy, Head of Medical Genetics department at the
Children's Hospital La Timone (Marseille, France) was next to speak
for its presentation on the diagnostic approaches in FSHD by
molecular combing use. « Facioscapulohumeral Muscular
Dystrophy, the 3rd most spread myopathy, is perfect to demonstrate
the benefits of the molecular combing technology. This one allows
to update the genetic complexity of this disease while the other
technologies currently used, including Next-Generation sequencing
ones, don’t answer all the expectations. Off course, these NGS will
evolve in the future but in our department we study pathologies
which remain undetectable by them. Moreover, the molecular combing
allows research in other pathologies, as the children
leukemia”.
Finally, Dr Petr Janda, CEO of PCS (Prague Clinical Services),
the CRO in charge of the HPV clinical trial in Czech Republic and
Dr Anne Jacquet, Director of Biomedical Research of Genomic Vision,
presented the interim results of EXPL-HPC-002 study
(http://www.genomicvision.com/wp-content/uploads/CP_GV_10-mai_HPV_FINAL-1.pdf).
Dr Petr Janda reminded: “The current diagnosis tests of the
cervical cancer are limited in terms of sensibility or
specificity.” Beyond the promising results presented by the Genomic
Vision’s HPV test, both speakers explained: “The use of the
molecular combing allowed, for the first time, to visualize, to
characterize and to quantify the number of HPV genomes integrated
in the DNA of the female patients. This opens a new way in the
diagnosis and the follow-up of the patients having a risk of
cervical cancer associated with HPV virus by allowing the selection
between the patients who are infected by the HPV virus but who will
naturally eliminate it without developing a cancer and those who
will require an appropriate care considering the rates of virus
integration.”
Through the presentation of the different IVD programs of
Genomic Vision, Aaron Bensimon concluded: “The use of molecular
combing presents a new paradigm on a large range of applications.
This potential encourages us to build closer relationships with the
clinicians, who are at the heart of the diagnosis of the genetic
diseases and facing its deadlocks. Thanks to closer relationships
with clinicians, we will be able to develop new tests, like we are
doing for the SMA test."
The whole conference of the R&D Day will be available for
consultation on the Genomic Vision’s website in a few days.
ABOUT GENOMIC VISIONGENOMIC VISION is a company
specialized in the development of diagnostic solutions for the
early detection of cancers and serious genetic diseases and tools
for life sciences research. Through the DNA Molecular Combing, a
strong proprietary technology allowing to identify genetic
abnormalities, GENOMIC VISION stimulates the R&D productivity
of the pharmaceutical companies, the leaders of the diagnostic
industry and the research labs.The Company develops a robust
portfolio of diagnostic tests (breast, ovarian and colorectal
cancers, myopathies) and analysis tools (DNA replication,
biomarkers discovery, gene editing quality control). Based near
Paris, in Bagneux, the Company has approximately 60 employees.
GENOMIC VISION is a public listed company listed in compartment C
of Euronext’s regulated market in Paris (Euronext: GV - ISIN:
FR0011799907). For further information, please visit
www.genomicvision.com
Member of CAC® Mid & Small and CAC®
All-Tradable indexes
FORWARD LOOKING STATEMENT
This press release contains implicitly or explicitly certain
forward-looking statements concerning Genomic Vision and its
business.
Such forward-looking statements are based on assumptions that
Genomic Vision considers to be reasonable. However, there can be no
assurance that such forward-looking statements will be verified,
which statements are subject to numerous risks, including the risks
set forth in the “Risk Factors” section in its Document de
Reference filed with the French Autorité des Marchés Financiers
(AMF) on March 28, 2017, under number R.17-009, available on the
web site of Genomic Vision (www.genomicvision.com) and to the
development of economic conditions, financial markets and the
markets in which Genomic Vision operates. The forward-looking
statements contained in this press release are also subject to
risks not yet known to Genomic Vision or not currently considered
material by Genomic Vision. The occurrence of all or part of such
risks could cause actual results, financial conditions, performance
or achievements of Genomic Vision to be materially different from
such forward-looking statements.
This press release and the information contained herein do not
constitute and should not be construed as an offer or an invitation
to sell or subscribe, or the solicitation of any order or
invitation to purchase or subscribe for Genomic Vision shares in
any country. The distribution of this press release in certain
countries may be a breach of applicable laws. The persons in
possession of this press release must inquire about any local
restrictions and comply with these restrictions.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170515006041/en/
Genomic VisionAaron BensimonCo-founder, Chairman &
CEOTel. : +33 1 49 08 07
50investisseurs@genomicvision.comorMilestonesPress
RelationsBruno ArabianTel. : +33 1 83 62 34
84barabian@milestones.frorNewCapInvestor RelationsDušan
Orešanský / Emmanuel HuynhTel. : +33 1 44 71 94 92gv@newcap.eu
Goldfield (AMEX:GV)
Historical Stock Chart
From Apr 2024 to May 2024
Goldfield (AMEX:GV)
Historical Stock Chart
From May 2023 to May 2024